Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge

Vaccine

Volumn 27, Issue 8, 2009, Pages 1266-1271

  Romero, Jackeline F ^a   Ciabattini, Annalisa ^b   Guillaume, Philippe ^c   Frank, Geraldine ^a   Ruggiero, Paolo ^d   Pettini, Elena ^b   Del Giudice, Giuseppe ^d   Medaglini, Donata ^b   Corradin, Giampietro ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF SIENA   (Italy)

^c Ludwing Institute for Cancer Research   (Switzerland)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

LTK63; Parasitic protozoan; Rodent; T lymphocytes

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; ESCHERICHIA COLI ENTEROTOXIN; MALARIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; LIVER; MALARIA; MALARIA CONTROL; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; B-LYMPHOCYTES; BACTERIAL TOXINS; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PLASMODIUM BERGHEI; PROTOZOAN PROTEINS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 58749088034     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.010     Document Type: Article

References (35)

1. Girard M.P., Reed Z.H., Friede M., and Kieny M.P. A review of human vaccine research and development: malaria. Vaccine 25 Feb 19 (9) (2007) 1567-1580
2. Kiyono H., and Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 4 Sep (9) (2004) 699-710
3. Wu H.Y., and Russell M.W. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res 16 2 (1997) 187-201
4. Medaglini D., Ciabattini A., Cuppone A.M., Costa C., Ricci S., Costalonga M., et al. In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii. Infect Immun 74 May (5) (2006) 2760-2766
5. Bowe F., Lavelle E.C., McNeela E.A., Hale C., Clare S., Arico B., et al. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect Immun 72 Jul (7) (2004) 4052-4060
6. Unger W.W., Jansen W., Wolvers D.A., van Halteren A.G., Kraal G., and Samsom J.N. Nasal tolerance induces antigen-specific CD4+ CD25- regulatory T cells that can transfer their regulatory capacity to naive CD4+ T cells. Int Immunol 15 Jun (6) (2003) 731-739
7. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 56 Dec (4) (1992) 622-647
8. Levine M.M., Kaper J.B., Black R.E., and Clements M.L. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 47 Dec (4) (1983) 510-550
9. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19 Mar 21 (17-19) (2001) 2534-2541
10. Rappuoli R., Pizza M., Douce G., Dougan G., and Structure. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 20 Nov (11) (1999) 493-500
11. Simmons C.P., Hussell T., Sparer T., Walzl G., Openshaw P., and Dougan G. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J Immunol 166 Jan 15 (2) (2001) 1106-1113
12. Williams A.E., Edwards L., Humphreys I.R., Snelgrove R., Rae A., Rappuoli R., et al. Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease. J Immunol 173 Dec 15 (12) (2004) 7435-7443
13. Marchetti M., Rossi M., Giannelli V., Giuliani M.M., Pizza M., Censini S., et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16 Jan (1) (1998) 33-37
14. Neidleman J.A., Vajdy M., Ugozzoli M., Ott G., and O'Hagan D. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. Immunology 101 Sep (1) (2000) 154-160
15. Stephenson I., Zambon M.C., Rudin A., Colegate A., Podda A., Bugarini R., et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80 May (10) (2006) 4962-4970
16. Hirunpetcharat C., Stanisic D., Liu X.Q., Vadolas J., Strugnell R.A., Lee R., et al. Intranasal immunization with yeast-expressed 19 kD carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (yMSP119) induces protective immunity to blood stage malaria infection in mice. Parasite Immunol 20 Sep (9) (1998) 413-420
17. Arakawa T., Komesu A., Otsuki H., Sattabongkot J., Udomsangpetch R., Matsumoto Y., et al. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect Immun 73 Nov (11) (2005) 7375-7380
18. Bargieri D.Y., Rosa D.S., Braga C.J., Carvalho B.O., Costa F.T., Espindola N.M., et al. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 26 Nov 11 (48) (2008) 6132-6142
19. Roggero M.A., Meraldi V., Lopez J.A., Eberl G., Romero J.C., Matile H., et al. The synthetic, oxidized C-terminal fragment of the Plasmodium berghei circumsporozoite protein elicits a high protective response. Eur J Immunol 30 Sep (9) (2000) 2679-2685
20. Meraldi V., Audran R., Romero J.F., Brossard V., Bauer J., Lopez J.A., et al. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine 21 Jun 2 (19-20) (2003) 2485-2491
21. Meraldi V., Romero J.F., Kensil C., and Corradin G. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites. Vaccine 23 Apr 15 (21) (2005) 2801-2812
22. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., and Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341 Sep 28 (6240) (1989) 323-326
23. Renggli J., Valmori D., Romero J.F., Eberl G., Romero P., Betschart B., et al. CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. Immunol Lett 46 May (1-2) (1995) 199-205
24. Doolan D.L., and Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J Immunol 165 Aug 1 (3) (2000) 1453-1462
25. Romero J.F., Ibrahim G.H., Renggli J., Himmelrich H., Graber P., and Corradin G. IL-12p40-independent induction of protective immunity upon multiple Plasmodium berghei irradiated sporozoite immunizations. Parasite Immunol 29 Nov (11) (2007) 541-548
26. Frevert U., and Nardin E. Cellular effector mechanisms against Plasmodium liver stages. Cell Microbiol 10 Oct (10) (2008) 1956-1967
27. Atherton F.R., Hall M.J., Hassall C.H., Lambert R.W., Lloyd W.J., and Ringrose P.S. Phosphonopeptides as antibacterial agents: mechanism of action of alaphosphin. Antimicrob Agents Chemother 15 May (5) (1979) 696-705
28. Giuliani M.M., Del Giudice G., Giannelli V., Dougan G., Douce G., Rappuoli R., et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 187 Apr 6 (7) (1998) 1123-1132
29. Asanuma H., Thompson A.H., Iwasaki T., Sato Y., Inaba Y., Aizawa C., et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. J Immunol Methods 202 Mar 28 (2) (1997) 123-131
30. Watanabe H., Ohtsuka K., Kimura M., Ikarashi Y., Ohmori K., Kusumi A., et al. Details of an isolation method for hepatic lymphocytes in mice. J Immunol Methods 146 Feb 5 (2) (1992) 145-154
31. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 Jan 9 (2) (1997) 86-91
32. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 Oct 16 (5388) (1998) 476-480
33. Nardin E., Zavala F., Nussenzweig V., and Nussenzweig R.S. Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parassitologia 41 Sep (1-3) (1999) 397-402
34. Walther M., Dunachie S., Keating S., Vuola J.M., Berthoud T., Schmidt A., et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 23 Jan 4 (7) (2005) 857-864
35. Tritto E., Muzzi A., Pesce I., Monaci E., Nuti S., Galli G., et al. The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature. J Immunol 179 Oct 15 (8) (2007) 5346-5357